EW Stock Recent News

Edwards Lifesciences cut TAVR guidance, stock price dropped by over 31%. Recent acquisitions and divestiture of the Critical Care business show strategic focus on the structural heart market. Analyst reiterates 'Strong Buy' rating with a fair value of $72 per share, confident in long-term growth potential.

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.

Major U.S. equities indexes were mixed after a report showing U.S. gross domestic product (GDP) grew at a greater-than-expected annualized rate of 2.8% in the second quarter.

Edwards Lifesciences (EW) shares swooned Thursday, dropping after the company damped expectations for heart valve replacement sales growth on Wednesday.

Edwards Lifesciences Corp EW reported Wednesday second-quarter adjusted EPS of 70 cents, beating the consensus of 69 cents.

Edwards Lifesciences Corporation EW reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.

Edwards Lifesciences (NYSE: EW ) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents.

Peijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System SUZHOU, China , July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, today commented on the expected acquisition of JenaValve Technology, Inc. ("JenaValve"), an exclusive technology licensing partner of Peijia, by Edwards Lifesciences ("Edwards"). On July 24, 2024, Edwards announced that it had entered into an agreement to acquire JenaValve, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is currently untreated today.

The medical-technologies company misses second-quarter sales estimates.